19070-16-7

Usage

Uses

Used in Chemical Synthesis:
CHLORO[3-(DIMETHYLAMINO)PROPYL]MAGNESIUM is used as a reagent in chemical synthesis for its strong base and nucleophilic properties, facilitating certain reactions that may be challenging with other compounds.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, CHLORO[3-(DIMETHYLAMINO)PROPYL]MAGNESIUM is used as an intermediate in the synthesis of complex organic molecules, potentially contributing to the development of new drugs.
Used in Material Science:
CHLORO[3-(DIMETHYLAMINO)PROPYL]MAGNESIUM may be employed as a component in the development of new materials, leveraging its unique chemical properties to create novel materials with specific characteristics.
Used in Research and Development:
In research and development settings, CHLORO[3-(DIMETHYLAMINO)PROPYL]MAGNESIUM is used as a subject of study to explore its chemical behavior, reactivity, and potential applications in various fields.

InChI:InChI=1/C5H12N.ClH.Mg/c1-4-5-6(2)3;;/h1,4-5H2,2-3H3;1H;/q;;+1/p-1/rC5H12ClMgN/c1-8(2)5-3-4-7-6/h3-5H2,1-2H3

Upstream product

• 109-54-6 3-(Dimethylamino)propyl chloride 
• 113836-41-2 11-oxo-2-<2-<(triphenylmethyl)oxy>ethyl>-6,11-dihydroxydibenzoxepin 
• 113836-39-8 2-(4,4-dimethyl-2-oxazolin-2-yl)-11-oxo-6,11-dihydrodibenzoxepin 
• 59795-23-2 10,11-dihydro-10,10,11,11-tetrafluoro-5H-dibenzo[a,d]cyclohepten-5-one 
• 3481-02-5 cyclopropyl phenyl ketone 
• 6203-08-3 methyl 5-norbornene-2-carboxylate 
• 5407-04-5 3-(dimethylamino)propyl chloride hydrochloride 

Downstream Products

• 19989-54-9 4-dimethylamino-1-(2-phenyl-benzothiazol-6-yl)-butan-1-ol 
• 38735-63-6 dimethyl-[3-(1-methyl-3-phenyl-1,3-dihydro-benzo[c]isoxazol-3-yl)-propyl]-amine 
• 38735-67-0 [3-(5-chloro-1-methyl-3-phenyl-1,3-dihydro-benzo[c]isoxazol-3-yl)-propyl]-dimethyl-amine 
• 521-80-2 N,N-dimethyl-3-(5H-dibenzo[a,d]cyclohepten-5-yl)-propylamine 
• 1116-77-4 4,4-diethoxy-N,N-dimethyl-1-butanamine 
• 86111-93-5 N¹,N¹,N⁴,N⁴-Tetramethyl-1-phenyl-butane-1,4-diamine 
• 114534-33-7 (4S,5S)-5-(3-Dimethylamino-propyl)-4-hydroxy-4-phenylethynyl-cyclohex-2-enone 
• 96245-66-8 4-<2-amino>phenyl>-4-(3-chlorophenyl)-4-hydroxy-N,N-dimethyl-1-butanamine 
• 25627-36-5 Dothiepin hydrochloride 
• 25627-39-8 dothiepin hydrochloride 
• 19947-10-5 4-Dimethylamino-N-(2-phenethyl-phenyl)-butyramide 
• 96245-70-4 (E)-4-(2-aminophenyl)-4-(3-chlorophenyl)-N,N-dimethylbut-3-en-1-amine 
• 96245-72-6 4-(3-chlorophenyl)-N,N-dimethyl-3-cinnolineethanamine 
• 96245-68-0 (Z)-4-<2-<<(4-methylphenyl)sulfonyl>amino>phenyl>-4-(3-chlorophenyl)-N,N-dimethylbut-3-en-1-amine 

Relevant academic research and scientific papers

Synthesis of new heteroleptic strontium complexes

A series of heteroleptic strontium complexes (1-9) using a combination of different aminoalkoxides and 2,2,6,6-tetramethyl-3,5-heptanedionate (tmhd) were prepared to examine the effect of the bulkiness and coordination ability of the aminoalkoxide ligand in these complexes as well as potential strontium precursors. All complexes were characterized by FT-IR, FT-NMR, elemental analyses, and thermo-gravimetric (TG) analyses. The crystal structure analyses of 1, 2, 4, and 5 demonstrate their stability in the dimer form and the unwillingness of the strontium atom to form more than six coordination bonds in these complexes. The complex 5 shows an unusual picture: the existence of one hexa-coordinated and one penta-coordinated strontium atom side by side in its dimer structure. The introduction of ether groups as coordination sites in complexes 6-9 led to a decrease in steric hindrance which resulted in the formation of the complex 7 as a tetramer. The complex 7 shows a unique Sr4O4cubane core where oxygen atoms undergo μ3-bridging between strontium atoms. The TG analyses show that the complexes exhibit a step-wise decomposition character, with the major mass losses in the region 150-400 °C.

Preparation method of escitalopram oxalate impurities

The application of the invention provides a brand-new preparation method of (R)-4-(dimethylamino)-1-(1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-yl)-butyl-1-ketone to provide a basis for qualitative and quantitative analysis of impurity profiles in escitalopram oxalate finished products, thereby having a significant role in quality control of escitalopram oxalate and being capable of promoting the safe use of depressive patients.

SELECTIVE ALLOSTERIC MODULATORS OF THE SEROTONIN TRANSPORTER

Compounds of formula (I) are provided wherein R1 represents H, CN and CF3; R2 represents 1-naphthyl, 3,5-dichlorophenyl, 4-(4-fluorophenylthio)phenyl or phenyl substituted with one or more substituent selected from halogen, methoxy, cyano, methyl and trifluorom ethyl; R3 and R4 independently represent H, C1-3-alkyl or R3 and R4 together with the carbon atom to which they are attached form a C4-6-cyclic alkyl; R5 and R6 independently represent H or C1-6-alkyl; n represents 1 or 2; and pharmaceutically acceptable acid addition salts thereof, provided that if n is 2 then R2 is not 1-naphthyl, which compounds are selective allosteric SERT ligands.

NOVEL PHTHALOCYANINE DERIVATIVES FOR THERAPEUTIC USE

There are described phthalocyanine derivates, the pharmaceutical compositions and the medical devices that contain them, possibly in combination with chelating agents, such as EDTA, useful for treating, by means of photodynamic therapy, diseases character

Preparation of Escitalopram, Its Salts and Intermediates

The present patent application relates to an improved process for the preparation of escitalopram, its salts and intermediates. It also relates to a novel crystalline form S of citalopram diol intermediate, process for preparation and its use in the preparation of citalopram, escitalopram and their salts.

PREPARATION OF ESCITALOPRAM, ITS SALTS AND INTERMEDIATES

The present patent application relates to an improved process for the preparation of escitalopram, its salts and intermediates. It also relates to a novel crystalline form S of citalopram diol intermediate, process for preparation and its use in the preparation of citalopram, escitalopram and their salts.

From the selective serotonin transporter inhibitor citalopram to the selective norepinephrine transporter inhibitor talopram: Synthesis and structure-activity relationship studies

Citalopram and talopram are structurally closely related, but they have very distinct pharmacological profiles as selective inhibitors of the serotonin and norepinephrine transporters, respectively. A systematic structure-activity relationship study was p

Method for the preparation of citalopram

A method for the preparation of citalopram and its pharmaceutically acceptable salts is described; it's obtained starting from 5-cyanophthalide by reaction with a mixture of 4-fluorophenyl magnesium bromide and 3-dimethylaminopropyl magnesium chloride. The intermediate obtained is showed here-below: wherein X is an halogen, preferably chlorine or bromine, which is cyclized without any isolation.

IMPROVED PROCESS FOR THE MANUFACTURE OF CITALOPRAM HYDROBROMIDE

The present invention describes an improved process for the preparation of extremely pure 1-(4'-Fluorophenyl)-1-(3-dimethylaminopropyl)-5-phthalanecarbonitrile and its bromide salt (citalopram hydrobromide), which is a well known antidepressant. Other aspect of the invention are isolation of crystalline (4-Bromo-2-hydroxymethyl)phenyl-(4-fluorophenyl)-3-(dimethylaminopropyl)methanol (Bromodiol) and conversion of desmethylcitalopram which is formed during the cyanide exchange reaction, to Citalopram by heating with a mixture of formaldhyde and formic acid in chloroform. The resulting citalopram is conventionally purified using extraction methodology.

ONE POT SYNTHESIS OF CITALOPRAM FROM 5-CYANOPHTHALIDE

A process for one pot synthesis of citalopram is disclosed. The process comprises subjecting 5-cyano phthalide to Grignard reduction followed cyclization and followed by C-alkylation reaction to obtain citalopram without isolation and purification of any intermediates. In another embodiment, 5-cyano phthalide is subjected to sequential Grignard reactions followed by cyclization to obtain citalopram without isolation and purification of any intermediate stages.